Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Molecular and functional imaging for detection of lymph node metastases in prostate cancer.

Fortuin A, Rooij Md, Zamecnik P, Haberkorn U, Barentsz J.

Int J Mol Sci. 2013 Jul 3;14(7):13842-75. doi: 10.3390/ijms140713842. Review.

2.

Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.

Fortuin AS, Deserno WM, Meijer HJ, Jager GJ, Takahashi S, Debats OA, Reske SN, Schick C, Krause BJ, van Oort I, Witjes AJ, Hoogeveen YL, van Lin EN, Barentsz JO.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):712-8. doi: 10.1016/j.ijrobp.2011.12.093. Epub 2012 Mar 13.

3.
4.

[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.

Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S.

BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x. Epub 2012 Apr 23.

5.

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.

J Urol. 2016 May;195(5):1436-43. doi: 10.1016/j.juro.2015.12.025. Epub 2015 Dec 9.

PMID:
26682756
6.

Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.

Ergul N, Kadioglu H, Yildiz S, Yucel SB, Gucin Z, Erdogan EB, Aydin M, Muslumanoglu M.

Acta Radiol. 2015 Aug;56(8):917-23. doi: 10.1177/0284185114539786. Epub 2014 Jul 10.

PMID:
25013091
7.

Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer.

Birkhäuser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A, Thoeny HC.

Eur Urol. 2013 Dec;64(6):953-60. doi: 10.1016/j.eururo.2013.07.032. Epub 2013 Jul 30.

PMID:
23916692
8.

A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured.

Meijer HJ, Debats OA, van Lin EN, Witjes JA, Kaanders JH, Barentsz JO.

Radiat Oncol. 2013 Jul 30;8:190. doi: 10.1186/1748-717X-8-190.

9.

Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.

Cooper KL, Meng Y, Harnan S, Ward SE, Fitzgerald P, Papaioannou D, Wyld L, Ingram C, Wilkinson ID, Lorenz E.

Health Technol Assess. 2011 Jan;15(4):iii-iv, 1-134. doi: 10.3310/hta15040. Review.

10.

Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT.

Vag T, Heck MM, Beer AJ, Souvatzoglou M, Weirich G, Holzapfel K, Rummeny EJ, Schwaiger M, Krause BJ, Eiber M.

Eur Radiol. 2014 Aug;24(8):1821-6. doi: 10.1007/s00330-014-3240-8. Epub 2014 Jun 3. Erratum in: Eur Radiol. 2014 Aug;24(8):1827.

PMID:
24889997
11.

[11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy.

Schumacher MC, Radecka E, Hellström M, Jacobsson H, Sundin A.

Scand J Urol. 2015 Feb;49(1):35-42. doi: 10.3109/21681805.2014.932840. Epub 2014 Jul 8.

PMID:
25001948
12.

Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment.

Hegemann NS, Wenter V, Spath S, Kusumo N, Li M, Bartenstein P, Fendler WP, Stief C, Belka C, Ganswindt U.

Radiat Oncol. 2016 Mar 11;11:37. doi: 10.1186/s13014-016-0615-9.

13.

MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.

Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Fütterer JJ, Barentsz J.

Lancet Oncol. 2008 Sep;9(9):850-6. doi: 10.1016/S1470-2045(08)70203-1. Epub 2008 Aug 15.

PMID:
18708295
14.

Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging.

Heesakkers RA, Jager GJ, Hövels AM, de Hoop B, van den Bosch HC, Raat F, Witjes JA, Mulders PF, van der Kaa CH, Barentsz JO.

Radiology. 2009 May;251(2):408-14. doi: 10.1148/radiol.2512071018.

PMID:
19401573
15.

Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.

Van den Bergh L, Lerut E, Haustermans K, Deroose CM, Oyen R, Isebaert S, Budiharto T, Ameye F, Mottaghy FM, Bogaerts K, Van Poppel H, Joniau S.

Urol Oncol. 2015 Mar;33(3):109.e23-31. doi: 10.1016/j.urolonc.2014.11.008. Epub 2015 Feb 2.

PMID:
25655681
16.

18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.

Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, Khoder W, Bartenstein P, Stief CG, Loidl W, Seitz M.

Eur Urol. 2013 May;63(5):792-6. doi: 10.1016/j.eururo.2012.08.003. Epub 2012 Aug 10.

PMID:
22902037
17.

Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography.

Jilg CA, Schultze-Seemann W, Drendel V, Vach W, Wieser G, Krauss T, Jandausch A, Hölz S, Henne K, Reske SN, Grosu AL, Weber WA, Rischke HC.

J Urol. 2014 Jul;192(1):103-10. doi: 10.1016/j.juro.2013.12.054. Epub 2014 Feb 8.

PMID:
24518792
18.

Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT.

Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Barentsz JO.

Eur Radiol. 2004 Sep;14(9):1707-12. Epub 2004 Jul 13.

PMID:
15249979
19.

Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.

Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, Oyen R, Ameye F, Bogaerts K, Haustermans K, Van Poppel H.

Eur Urol. 2011 Jul;60(1):125-30. doi: 10.1016/j.eururo.2011.01.015. Epub 2011 Jan 18.

PMID:
21292388
20.

SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer.

Motomura K, Ishitobi M, Komoike Y, Koyama H, Noguchi A, Sumino H, Kumatani Y, Inaji H, Horinouchi T, Nakanishi K.

Ann Surg Oncol. 2011 Nov;18(12):3422-9. doi: 10.1245/s10434-011-1710-7. Epub 2011 May 24.

PMID:
21607775

Supplemental Content

Support Center